<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829539</url>
  </required_header>
  <id_info>
    <org_study_id>URCC19185</org_study_id>
    <secondary_id>NCI-2020-07175</secondary_id>
    <secondary_id>URCC19185</secondary_id>
    <secondary_id>URCC-19185</secondary_id>
    <secondary_id>URCC19185</secondary_id>
    <secondary_id>R01CA214647</secondary_id>
    <secondary_id>UG1CA189961</secondary_id>
    <nct_id>NCT04829539</nct_id>
  </id_info>
  <brief_title>Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy</brief_title>
  <official_title>Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester NCORP Research Base</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with&#xD;
      stage I-III cancer who are receiving chemotherapy. Chemotherapy can cause side effects such&#xD;
      as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia&#xD;
      can be described as difficulty falling asleep, waking up many times during the night or&#xD;
      waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality&#xD;
      of life. This trial may help researchers determine which treatment works better in reducing&#xD;
      insomnia, BBT-CI or HEAL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the efficacy of BBT-CI compared to HEAL as measured by the patient report&#xD;
      outcome (PRO) of insomnia (i.e., the Insomnia Severity Index) at post-intervention.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the efficacy of BBT-CI compared to HEAL on sleep efficiency as measured via&#xD;
      actigraphy at post intervention.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 groups.&#xD;
&#xD;
      GROUP I (BBT-CI): Patients complete face to face/video sessions with a trained staff member&#xD;
      over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1&#xD;
      or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients&#xD;
      also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy&#xD;
      cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are&#xD;
      separated by 3 weeks), and days 28 and 35.&#xD;
&#xD;
      GROUP II (HEAL): Patients complete face to face/video sessions with a trained staff member&#xD;
      over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1&#xD;
      or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients&#xD;
      also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy&#xD;
      cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are&#xD;
      separated by 3 weeks), and days 28 and 35.&#xD;
&#xD;
      After completion of study, patients are followed for up to 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the Insomnia Severity Index (ISI) total score</measure>
    <time_frame>Baseline to day 42</time_frame>
    <description>The Insomnia Severity Index (ISI) is a validated self-report measure of insomnia. A 5-point Likert Scale of seven questions is used to rate each item (0=no problem; 4=very severe problem), yielding a total score ranging from 0-28 with higher scores indicating higher severity of insomnia. A linear mixed effects analysis of covariance model (ANCOVA) will be used to assess the statistical significance of the differences in mean change between BBT-CI and HEAL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Sleep Efficiency assessed via Actigraphy</measure>
    <time_frame>Baseline to day 42</time_frame>
    <description>Actigraphy will assess sleep efficiency, calculated as the percent of total sleep time to time in bed. Higher percentage indicates better sleep efficiency. A linear mixed effects analysis of covariance model (ANCOVA) will be used to assess the statistical significance of the differences in mean change between BBT-CI and HEAL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Group I (BBT-CI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (HEAL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients complete face to face/video sessions with a trained staff member over 60 minutes each on day 0 and day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks). Patients also complete phone sessions over 15 minutes each on day 7, day 14 (if patient's chemotherapy cycles are separated by 1 or 2 weeks) or day 21 (if patient's chemotherapy cycles are separated by 3 weeks), and days 28 and 35.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Receive BBT-CI</description>
    <arm_group_label>Group I (BBT-CI)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Receive HEAL</description>
    <arm_group_label>Group II (HEAL)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (BBT-CI)</arm_group_label>
    <arm_group_label>Group II (HEAL)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Group I (BBT-CI)</arm_group_label>
    <arm_group_label>Group II (HEAL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be diagnosed with cancer stage I, II or III&#xD;
&#xD;
          -  Be currently receiving any cytotoxic chemotherapy (can be cytotoxic chemotherapy alone&#xD;
             or in combination with biologics and/or antibodies)&#xD;
&#xD;
          -  Report sleep disturbance of 10 or greater (sum total of all 7 items) on the Insomnia&#xD;
             Severity Index&#xD;
&#xD;
          -  Have a score of 2, 1, or 0 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status scale&#xD;
&#xD;
          -  Be able to speak, understand and read English to participate in the study assessments&#xD;
             and interventions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be diagnosed with cancer stage IV&#xD;
&#xD;
          -  Have any type of unstable comorbid medical or psychiatric condition that would&#xD;
             prohibit completion of study assessments or intervention per physician or physician's&#xD;
             designee&#xD;
&#xD;
          -  Be scheduled to receive active radiation prior to the completion of BBT-CI/HEAL&#xD;
             interventions&#xD;
&#xD;
          -  Have a documented or physician's diagnosis of obstructive sleep apnea or restless leg&#xD;
             syndrome (even if controlled)&#xD;
&#xD;
          -  Be engaged in a formal Cognitive Behavioral Therapy for Insomnia program presently or&#xD;
             in the past 30 days. Use of psychotropics and sleep medication are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oxana Palesh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Mustian</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rochester NCORP Research Base</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kari Gilliland</last_name>
    <phone>585-275-6303</phone>
    <email>URCC_19185@URMC.Rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Spath</last_name>
    <phone>585-275-1364</phone>
    <email>URCC_19185@URMC.Rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester NCORP Research Base</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Gilliland</last_name>
      <phone>585-275-6303</phone>
      <email>URCC_19185@URMC.Rochester.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester NCORP Research Base</investigator_affiliation>
    <investigator_full_name>Karen Mustian</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

